Ignite Creation Date:
2024-05-05 @ 6:36 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00510107
Status:
UNKNOWN
Last Update Posted:
2007-08-01
First Post:
2007-07-31
Brief Title:
Weekly Docetaxel Plus Cisplatin or Oxaliplatin for AGC
Sponsor:
Gachon University Gil Medical Center
Organization:
Gachon University Gil Medical Center
Study Overview
Official Title:
A Randomized Phase II Trial of Weekly DocetaxelCisplatin Versus Weekly DocetaxelOxaliplatin in Previously Untreated Patients With Advanced Gastric Cancer
Status:
UNKNOWN
Status Verified Date:
2007-07
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the efficacy and safety of weekly administered combination of docetaxelcisplatin and docetaxeloxaliplatin in chemotherapy-naïve patients with advanced gastric cancer The primary endpoint will be the response rate
Detailed Description:
Gastric cancer is the most frequently occurring malignancy in Korea and is one of the main causes of cancer death While treatment options for AGC have expanded in recent years to include newer agents such as taxanes irinotecan and oxaliplatin myelosuppression remains a problem Recently weekly schedule of docetaxel is appealing due to limited incidence of severe myelosuppression compared with standard 3-weekly regimen This altered toxicity profile suggests a potential for better tolerance and increased dose intensity
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None